

DCAT

TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

Tuesday
July 12, 2016

DCAT
SharpSourcing
2016
EDUCATION FORUMS • NETWORKING KEYNOTE • SPEAKER

1. [Shire Completes \\$32 Billion Acquisition of Baxalta](#)

Shire has completed its previously announced \$32-billion acquisition of the specialty biopharmaceutical company, Baxalta. Through the combination, Shire expects to deliver double-digit compound annual top-line growth with over \$20 billion in annual projected revenue by 2020 and approximately 65% of total annual revenues being generated by rare disease products. [Read More](#)

2. [Merck & Co. To Acquire Afferent Pharmaceuticals](#)

Merck & Co. has agreed to acquire Afferent Pharmaceuticals, a privately held pharmaceutical company, in a deal valued up to \$1.25 billion. Afferent is developing therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly managed, neurogenic conditions. [Read More](#)

3. [Fujifilm Diosynth Biotechnologies, Merck To Invest \\$60 Million for Microbial Biologics Facility](#)

Fujifilm Diosynth Biotechnologies, a contract biologics manufacturer, is in the process of establishing a long-term collaboration with MSD, the name for Merck & Co. outside the US and Canada, to invest in and operate a large-scale microbial biologics facility for the supply of active pharmaceutical ingredients for Fujifilm Diosynth's customers. The collaboration involves a \$60-million investment by MSD at its Brinny manufacturing plant in Innishannon, County Cork, Ireland. [Read More](#)

4. [Lupin Recalls Select Lots of the Antibiotic Ceftriaxone](#)

Lupin Pharmaceutical has voluntarily recalled 13 lots consisting of 54,472 vials in various dosage forms of the antibiotic, ceftriaxone for injection, due to the intermediates of the active pharmaceutical ingredient failing specifications. [Read More](#)

5. [Sun Pharma Divests Two Manufacturing Facilities](#)

As part of its manufacturing consolidation in the US, Mumbai-headquartered Sun Pharmaceuticals Industries has agreed to divest two oral solid dosage manufacturing facilities in Philadelphia, Pennsylvania and Aurora, Illinois, along with 15 related pharmaceutical products to Frontida BioPharm. [Read More](#)

6. [Sanofi Continues \\$9.3 Billion Takeover Bid of Medivation](#)

In its continuing interest to acquire the biopharmaceutical company, Medivation, Sanofi has filed an investor presentation with the US Securities and Exchange Commission in connection with its proposed \$9.3 billion takeover bid. Medivation has thus far rejected Sanofi's efforts, first rejecting a proposed offer in late April and again in early May. Sanofi then took the strategy of seeking to replace the Medivation board, a process that is expected to end no later than August 1. [Read More](#)

7. [AstraZeneca Divests Anesthesia Portfolio to Aspen](#)

AstraZeneca has entered into a commercialization agreement with Aspen Global, part of the Aspen Group, for rights to its global anesthesia portfolio outside the US in a deal valued up to \$770 million

and covering seven products. AstraZeneca had earlier divested the US rights to the products to Abraxis, now part of Fresenius Kabi, in 2006. [Read More](#)

8. [FDA Takes Action Against Sale of Unapproved Rx Products](#)

The FDA, in partnership with international regulatory and law enforcement agencies, has taken action against 4,402 websites that illegally sell unapproved prescription drugs to US consumers. This effort was part of Operation Pangea IX, the Ninth Annual International Internet Week of Action, a global cooperative effort, led by Interpol, to combat the unlawful sale and distribution of illegal and potentially counterfeit medical products on the Internet. [Read More](#)

9. [FDA Advisory Committee Recommends Pfizer's Abuse-Deterrent Opioid.....](#)

A FDA Advisory Committee has voted in favor of approval of Pfizer's ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules as a long-term opioid treatment. ALO-02 is an investigational oxycodone formulated with sequestered naltrexone technology designed to help deter oral and non-oral abuse when crushed. [Read More](#)

10. [...And Also Recommends Teva's Abuse-Deterrent Opioid](#)

A FDA advisory committee has also recommended for approval Teva's long-term opioid, Vantrela ER, an extended-release formulation of hydrocodone bitartrate with Teva's proprietary abuse deterrence technology. [Read More](#)

****Upcoming DCAT Event Preview****

[Pharma Companies' Evolving Expectations of Suppliers](#)

Pharmaceutical companies and suppliers alike emphasize the value from having more strategic and collaborative relationships. But how does this interest translate to basic issues, such as payment terms and inventory management, so that it may be mutually beneficial to each party? Is this possible, and if so how? Addressing working capital requirements will be one topic addressed at the Suppliers' Forum at **DCAT Sharp Sourcing**, which will be held Tuesday, July 12, in New Brunswick, NJ. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Amum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org